Erste Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Erste Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.96M	Hold	73,100	–	–	0.02%	381
2026 Q1	$1.56M	Hold	73,100	–	–	0.01%	396
2025 Q4	$2.09M	Hold	73,100	–	–	0.02%	347
2025 Q3	$1.36M	Hold	73,100	–	–	0.01%	385
2025 Q2	$1M	Hold	73,100	–	–	0.01%	505
2025 Q1	$1.15M	Hold	73,100	–	–	0.01%	362
2024 Q4	$1.05M	Buy	73,100 +62,000	+559%	+$679K	0.01%	381
2024 Q3	$104K	Hold	11,100	–	–	﹤0.01%	493
2024 Q2	$105K	Hold	11,100	–	–	﹤0.01%	490
2024 Q1	$106K	Hold	11,100	–	–	﹤0.01%	489
2023 Q4	$36.6K	Hold	11,100	–	–	﹤0.01%	516
2023 Q3	$61.5K	Hold	11,100	–	–	﹤0.01%	509
2023 Q2	$92.5K	Hold	11,100	–	–	﹤0.01%	520
2023 Q1	$121K	Hold	11,100	–	–	﹤0.01%	524
2022 Q4	$162K	Hold	11,100	–	–	﹤0.01%	517
2022 Q3	$207K	Hold	11,100	–	–	﹤0.01%	496
2022 Q2	$246K	Hold	11,100	–	–	0.01%	496
2022 Q1	$208K	Hold	11,100	–	–	﹤0.01%	503
2021 Q4	$227K	Hold	11,100	–	–	﹤0.01%	486
2021 Q3	$251K	Hold	11,100	–	–	0.01%	463
2021 Q2	$287K	Hold	11,100	–	–	0.01%	455
2021 Q1	$299K	Buy	+11,100	New	+$347K	0.01%	427

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Erste Asset Management's ARQT Position: Q2 2026 in Review

Erste Asset Management held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 73,100 shares worth $1.96M. The position accounts for 0.02% of the portfolio, ranked #381.

Erste Asset Management first reported a position in ARQT in Q1 2021 and has held it in 22 quarters since. The position peaked at $2.09M in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Erste Asset Management held 73,100 shares of Arcutis Biotherapeutics worth $1.96M as of Q2 2026.
Erste Asset Management left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
Arcutis Biotherapeutics made up 0.02% of Erste Asset Management's portfolio in Q2 2026, its #381 holding.
Erste Asset Management first reported a position in Arcutis Biotherapeutics in Q1 2021 and has held it in 22 quarters since.
Erste Asset Management's Arcutis Biotherapeutics position peaked at $2.09M in Q4 2025.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Erste Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.